Erick Gamelin - Nov 14, 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Development Officer
Signature
/s/ Adam D. Levy, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
Nov 14, 2025
Transactions value $
-$903
Form type
4
Date filed
11/18/2025, 04:30 PM
Previous filing
Aug 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gamelin Erick Chief Development Officer C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact 2025-11-18 0001950551

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability -$903 -403 -2.57% $2.24 15.3K Nov 14, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.